I know. I know. You are totally right. It did. But Leo has never pr'd that way. And what was seen in mice is past tense now in relation to human trial. He says they are presenting data from current human trial and calls it, for first time, a p53-activating substance.

In past pr's he has said: "Kevetrin™, the Company’s novel drug in development for multi-drug resistant cancers",  "Kevetrin™, the Company’s flagship anti-cancer drug",  "Kevetrin, Cellceutix’s flagship cancer drug candidate",  "Kevetrin™, the Company’s novel drug in development for multi-drug resistant cancers"...

You know I'm not a fan of reading between the lines. Like to stick with what has been said. Do think this statement and it's construction are unusual and meaningful!